{"abortion spontaneous": 2.6, "abscess": 10.92, "adverse event": 2.75, "alanine aminotransferase increased": 5.14, "application site erythema": 4.91, "aspartate aminotransferase increased": 5.19, "ataxia": 6.05, "autoimmune hepatitis": 9.86, "autoimmune thyroiditis": 5.49, "breast cancer": 6.44, "cardiomyopathy": 4.65, "cellulitis": 4.18, "depressed mood": 2.84, "depression": 4.68, "device operational issue": 26.57, "diplopia": 2.02, "drug delivery system malfunction": 9.13, "drug-induced liver injury": 3.16, "erysipelas": 4.83, "expanded disability status scale score increased": 126.72, "gait disturbance": 3.44, "gait inability": 2.45, "gamma-glutamyltransferase increased": 10.88, "hemiparesis": 2.74, "hemiplegia": 2.79, "hepatic enzyme increased": 3.93, "hepatic function abnormal": 2.67, "hepatic steatosis": 3.78, "hepatitis": 4.53, "hyperthyroidism": 3.72, "impaired healing": 2.37, "incorrect dose administered by device": 16.0, "influenza like illness": 3.37, "injection site abscess": 172.11, "injection site atrophy": 68.47, "injection site bruising": 9.44, "injection site cellulitis": 79.67, "injection site discolouration": 37.74, "injection site erythema": 4.06, "injection site haematoma": 2.29, "injection site haemorrhage": 7.69, "injection site induration": 11.47, "injection site infection": 67.75, "injection site mass": 10.35, "injection site necrosis": 397.9, "injection site nodule": 11.71, "injection site oedema": 4.17, "injection site pain": 2.16, "injection site rash": 5.96, "injection site reaction": 7.92, "injection site ulcer": 215.18, "jaundice": 3.91, "leukocytosis": 2.39, "leukopenia": 3.89, "liver disorder": 2.12, "liver function test increased": 11.73, "lymphocyte count decreased": 5.24, "lymphopenia": 2.7, "maternal exposure during pregnancy": 2.7, "mobility decreased": 2.66, "multiple sclerosis": 47.55, "multiple sclerosis relapse": 45.13, "muscle rigidity": 3.38, "muscle spasticity": 21.74, "muscular weakness": 2.78, "nephrotic syndrome": 4.22, "neuromyelitis optica spectrum disorder": 21.25, "no adverse event": 2.45, "optic neuritis": 12.81, "panniculitis": 16.7, "paralysis": 2.68, "paraparesis": 11.16, "product dose omission issue": 3.99, "psychotic disorder": 2.92, "rash macular": 2.13, "raynaud's phenomenon": 5.65, "secondary progressive multiple sclerosis": 52.02, "skin necrosis": 58.75, "skin reaction": 5.57, "skin ulcer": 3.15, "suicide attempt": 3.02, "thrombotic microangiopathy": 9.01, "transaminases increased": 4.73, "urinary incontinence": 2.58, "vasculitis": 2.07}